Precigen Q2 2024 GAAP EPS $(0.23) Misses $(0.10) Estimate, Sales $717.00K Miss $1.28M Estimate
Portfolio Pulse from Benzinga Newsdesk
Precigen (NASDAQ:PGEN) reported Q2 2024 GAAP EPS of $(0.23), missing the $(0.10) estimate by 130%. Sales were $717K, missing the $1.28M estimate by 43.98%. This represents a 187.5% decrease in EPS and a 59.42% decrease in sales compared to the same period last year.
August 14, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Precigen reported disappointing Q2 2024 results with a GAAP EPS of $(0.23), missing estimates by 130%, and sales of $717K, missing estimates by 43.98%. Both EPS and sales showed significant declines compared to the same period last year.
The significant miss on both EPS and sales estimates, along with the large year-over-year declines, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100